6 December 2006

Contents

Conference reports

• Higher doses of ribavirin increases response rate to HCV treatment in coinfected patients: results from PRESCO study

• NNRTI levels high in HCV co-Infected patients with cirrhosis

• Viral load blips in children from the CHIPS cohort

• Multi-drug resistance in vertically infected children

• Wide disparity in switch to second-line therapy among children in CHIPS cohort

• Explanation for failure of TMC-125 (etravirine) in TMC227 study

• Saquinavir/r vs lopinavir/r: interim results from the Gemini study

• d4T associated with significantly increased risk of type-2 diabetes mellitus

• Drug interactions with darunavir (TMC-114)

• Drug interactions with etravirine (TMC-125)

• Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

• Community meeting on criminalisation of HIV transmission: jailing people for passing on HIV may threaten public health

Antiretrovirals

• TMC 114 recommended for conditional approval in Europe

• Atazanavir 300mg capsule approved in US

Treatment access

• Clinton price for new paediatric treatment

• Indian generic heat-stable ritonavir

• Generic FDC of efavirenz/tenofovir/FTC launched by Cipla

• Compulsory license for efavirenz in Thailand

Pregnancy

• US perinatal guidelines updated (2006)

Paediatric care

• US guidelines for the use of antiretroviral agents in paediatric HIV infection revised (2006)

Guidelines

• WHO EURO releases European clinical protocols for HIV/AIDS care and the report of the consultation on criminalisation of HIV/AIDS (2006)

• US adult treatment guidelines updated (Oct 2006)

On the web

• HIV and poverty in the UK

• PRN notebook –October 2006

• HIV inSite updates

• Management of metabolic and morphologic sequelae of HIV

• IAPAC European Sessions 2006

• IAVI Vax news